CBD Drug Interactions: Clinical Considerations

CBD has clinically relevant potential for drug–drug interactions, primarily through modulation of hepatic and intestinal metabolic pathways.

Cytochrome P450 Inhibition

CBD is a documented inhibitor of several cytochrome P450 (CYP) isoenzymes, including CYP3A4, CYP2C19, and CYP2C9. Inhibition of these pathways can increase plasma concentrations of co‑administered medications metabolized by these enzymes, particularly drugs with narrow therapeutic indices. [ncbi.nlm.nih.gov], [link.springer.com]

Medications of Concern

Medications frequently implicated in clinically meaningful interactions include:

• Antiepileptics (e.g., clobazam, valproic acid)
• Anticoagulants (e.g., warfarin)
• Immunosuppressants (e.g., tacrolimus)
• Certain antidepressants and benzodiazepines

Elevations in liver transaminases have been reported, particularly at higher CBD doses or when used concurrently with hepatotoxic medications. [droracle.ai]

Clinical Guidance

Clinicians should obtain a complete medication list, consider spacing CBD administration from other medications when appropriate, and monitor relevant laboratory values when initiating or titrating CBD. Risk is dose‑dependent and higher with pharmaceutical‑grade or high‑dose CBD use. [cannabiscl...icians.org]